Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Gilead Files HIV Triplet Biktarvy in Japan, JT Pact Termination Set for Jan. 1
The Japan arm of Gilead Sciences said on December 14 that it has filed a new drug application in Japan for its HIV triplet combining bictegravir, emtricitabine, and tenofovir alafenamide fumarate (TAF), known as Biktarvy overseas. The submission is based…
To read the full story
Related Article
- Gilead to Take Over MA for HIV Franchise from JT on Dec. 1
September 3, 2019
- JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
November 30, 2018
- Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
August 28, 2018
- Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…